**Scientific Articles published by H.C.Hemker** (selection, some key articles in bold).

References


84. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and antithrombin activities. Peyrou-V; Beguin-S; Boneu-B; Hemker-HC Thromb Haemost. 1997 Feb; 77(2): 312-6


132. Clustering of lipid-bound annexin V may explain its anticoagulant effect. Andree-HE; Stuart-MC; Hermens-WT; Reutelingsperger-CP; Hemker-HC; Frederik-PM; Willems-GM J-Biol-Chem. 1992 Sep 5; 267(25): 17907-12


134. Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells. Lindhout-T; Blezer-R; Schoen-P; Nordfang-O; Reutelingsperger-C; Hemker-HC Blood. 1992 Jun 1; 79(11): 2095-105


137. Elements from in vitro studies that help understand the action of heparins. Hemker-HC; Bendetowicz-AV; Beguin-S Thromb-Res-Suppl. 1991; 14: 1-10


143. Factor IX inhibits clotting because of the very high levels of its anticoagulant effects. Beguin-S; Dol-F; Hemker-HC Thromb-Haemost. 1991 Sep 2; 66(3): 306-9


148. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor [see comments] Galli-M; Comfurius-P; Maassen-C; Hemker-HC; de-Baets-MH; van-Breda-Vriesman-PJ; Barbuvi-T; Zwaal-RF; Bevers-EM Lancet. 1990 Jun 30; 335(8705): 1544-7


153. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Lindhout-T; Blezer-R; Schoen-P; Nordfang-O; Reutelingsperger-C; Hemker-HC Blood. 1990 Nov 30; 84(3): 464-8


156. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma. Beguin-S; Zwaal-RF; Lormeau-JC; Lindhout-T; Hemker-HC Thromb-Haemost. 1989 Feb 28; 61(1): 30-4


161. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Pieters-J; Lindhout-T; Hemker-HC Blood. 1989 Aug 15; 74(3): 1021-4


